Sign In
Buy ANIP
$75.23
+0.580 (+0.777%)
At Close: Jun 03, 2026
ANI Pharmaceuticals Reports Record Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Financial Guidance
06:50am, Friday, 27'th Feb 2026
PRINCETON, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the fourth quarter and ye
Krista Davis Sells 2,084 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock
04:44am, Wednesday, 25'th Feb 2026
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP - Get Free Report) SVP Krista Davis sold 2,084 shares of ANI Pharmaceuticals stock in a transaction that occurred on Thursday, February 19th. The stock was sold
Krista Davis Sells 1,730 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock
04:44am, Wednesday, 25'th Feb 2026
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP - Get Free Report) SVP Krista Davis sold 1,730 shares of the business's stock in a transaction dated Friday, February 20th. The stock was sold at an average pri
ANI Pharmaceuticals to Present at Upcoming Investor Conferences
06:50am, Tuesday, 24'th Feb 2026
PRINCETON, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with
ANI Pharmaceuticals (NASDAQ:ANIP) Insider Christopher Mutz Sells 5,323 Shares of Stock
04:49am, Tuesday, 24'th Feb 2026
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP - Get Free Report) insider Christopher Mutz sold 5,323 shares of the company's stock in a transaction dated Friday, February 20th. The stock was sold at an aver
Should You Buy ANI Pharmaceuticals Stock Before Q4 Earnings?
11:35am, Monday, 23'rd Feb 2026
ANIP gears up for Q4 earnings as Cortrophin Gel sales are expected to have surged, with rare disease momentum building despite generic competition pressures.
ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
11:01am, Friday, 20'th Feb 2026
ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026, at 8:00 a.m. ET
06:50am, Friday, 13'th Feb 2026
PRINCETON, N.J., Feb. 13, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company will release its fourth quarter and full year 2025 fin
Is ANI Pharmaceuticals (ANIP) a Great Value Stock Right Now?
10:40am, Friday, 06'th Feb 2026
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
ANI Pharmaceuticals (NASDAQ:ANIP) Stock Passes Below Fifty Day Moving Average – Here’s What Happened
04:58am, Tuesday, 27'th Jan 2026
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP - Get Free Report) passed below its fifty day moving average during trading on Monday. The stock has a fifty day moving average of $81.82 and traded as low as $
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?
10:41am, Friday, 16'th Jan 2026
Here is how ANI Pharmaceuticals (ANIP) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
ANIP vs. TEVA: Which Drug Stock Is the Better Buy Right Now?
09:56am, Friday, 16'th Jan 2026
ANI Pharmaceuticals' rare disease growth, led by surging Cortrophin Gel sales, is outpacing Teva's slower sales momentum in this head-to-head stock comparison.
ANIP Stock Rises 7% in a Week: Here's What You Should Know
09:35am, Thursday, 15'th Jan 2026
ANI Pharmaceuticals jumps 7% as 2026 guidance tops expectations, with strong sales and EPS growth fueled by momentum in the rare disease franchise.
ANI Pharmaceuticals, Inc. (ANIP) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
08:35pm, Tuesday, 13'th Jan 2026
ANI Pharmaceuticals, Inc. (ANIP) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
ANI Pharmaceuticals: Strong 2025 Finish And Bullish 2026 Guidance
11:53am, Tuesday, 13'th Jan 2026
ANI Pharmaceuticals delivered robust 2025 results and issued bullish 2026 guidance, targeting $1.055–$1.115 billion in revenues, up 60% year-over-year. Purified Cortrophin Gel remains the primary gr
